Association of immune-checkpoint inhibitors and the risk of immune-related colitis among elderly patients with advanced melanoma: real-world evidence from the SEER-Medicare database

• Asıl Yazarlar: Abdulaali R. Almutairi (Yazar), Marion Slack (Yazar), Brian L. Erstad (Yazar), Ali McBride (Yazar), Ivo Abraham (Yazar)
• Materyal Türü: Kitap
• Baskı/Yayın Bilgisi: SAGE Publishing, 2021-02-01T00:00:00Z.
• Konular: article
• Online Erişim: Connect to this object online.

Background: The use of anti-cytotoxic T-lymphocyte antigen 4 (anti-CTLA4) therapy (ipilimumab) and anti-programmed cell-death 1 (anti-PD1) agents (nivolumab and pembrolizumab) in advanced melanoma have been associated with immune-related adverse events (irAEs) including colitis. We aimed to estimate...